Bracco's new ultrasound contrast agent in trials:
This article was originally published in Clinica
Bracco is developing a new ultrasound contrast agent, BR14, which could provide doctors with more time to visualise the liver, kidneys, and possibly the heart, said the Milan, Italy-based company. Results from a 30-patient, phase I trial presented at last week's European Congress of Radiology meeting in Vienna, have shown that BR14 is a safe, effective agent in the kidneys and liver. Phase II trials are currently underway.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.